Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• In periocular basal cell carcinoma (BCC), vismodegib achieved a complete clinical response rate between 20-88% and an overall response rate of 68-100%, with disease progression observed at up to 14% and recurrence rates ranging from 0% to 31%. Quality of life improvements were noted.
• For advanced BCC, vismodegib showed a pooled overall response rate (ORR) of 68.5%, compared to 50.1% for sonidegib, indicating higher effectiveness of vismodegib.
• Topical patidegib reduced tumor burden in naive patients with stage II and III BCC but was ineffective in stage IV or previously treated cases, highlighting stage-specific benefits.
• For periocular BCC, common adverse effects of vismodegib include muscle cramps, dysgeusia, weight loss, and alopecia.
• In advanced BCC, vismodegib commonly causes muscle spasms (70.5%), dysgeusia (58.4%), and alopecia (59.9%), with weight loss occurring in 35.1% of cases. Comparatively, sonidegib exhibits slightly lower incidences of these effects but includes higher rates of nausea, diarrhea, increased creatine kinase levels, and decreased appetite.
• Topical patidegib for advanced BCC shows no systemic adverse effects, distinguishing it from systemic Hedgehog pathway inhibitors like vismodegib and sonidegib.
• There is no population type or subgroup information available in the reviewed studies.